TABLE 8.
Therapy-related adverse effects were reported as number per group after 3 and 6 months.
| Adverse effects | Control group (n = 30) | Digoxin group (n = 30) | p-value | |||
|---|---|---|---|---|---|---|
| 3 months | 6 months | 3 months | 6 months | 3 months (control vs. digoxin) | 6 months (control vs. digoxin) | |
| Malaise | 1 (3.3%) | 2 (6.7%) | 2 (6.7%) | 4 (13.3%) | 0.554 | 0.389 |
| Dizziness | 1 (3.3%) | 2 (6.7%) | 2 (6.7%) | 3 (10%) | 0.554 | 0.640 |
| Blurred vision | 0% | 1 (3.3%) | 0% | 2 (6.7%) | — | 0.554 |
| Nausea | 2 (6.7%) | 3 (10%) | 1 (3.3%) | 2 (6.7%) | 0.554 | 0.640 |
| Vomiting | 0% | 1 (3.3%) | 0% | 1 (3.3%) | 1.00 | 1.00 |
| Diarrhea | 1 (3.3%) | 2 (6.7%) | 1 (3.3%) | 1 (3.3%) | 1.00 | 0.554 |
| Anorexia | 2 (6.7%) | 3 (10%) | 1 (3.3%) | 2 (6.7%) | 0.554 | 0.640 |
| Abdominal pain | 0% | 1 (3.3%) | 1 (3.3%) | 2 (6.7%) | 0.313 | 0.554 |
| Dry mouth | 1 (3.3%) | 1 (3.3%) | 2 (6.7%) | 3 (10%) | 0.554 | 0.301 |
| Fatigue | 0% | 2 (6.7%) | 1 (3.3%) | 3 (10%) | 0.313 | 0.640 |
| Confusion | 1 (3.3%) | 1 (3.3%) | 1 (3.3%) | 2 (6.7%) | 1.00 | 0.554 |
| Weakness | 1 (3.3%) | 2 (6.7%) | 2 (6.7%) | 3 (10%) | 0.554 | 0.640 |
| Hair loss | 1 (3.3%) | 3 (10%) | 2 (6.7%) | 4 (13.3%) | 0.554 | 0.688 |
| Headache | 1 (3.3%) | 3 (10%) | 3 (10%) | 5 (16.7%) | 0.301 | 0.448 |
| Insomnia | 0% | 2 (6.7%) | 1 (3.3%) | 3 (10%) | 0.313 | 0.640 |
| Anxiety | 0% | 1 (3.3%) | 0% | 1 (3.3%) | — | 1.000 |
| Rash | 0% | 1 (3.3%) | 0% | 2 (6.7%) | — | 0.554 |
| WBC count decreased | 1 (3.3%) | 3 (10%) | 1 (3.3%) | 4 (13.3%) | 1.00 | 0.688 |
| Pharyngitis | 1 (3.3%) | 3 (10%) | 1 (3.3%) | 4 (13.3%) | 1.00 | 0.688 |
| Hypokalemia | 0% | 2 (6.7%) | 0% | 0% | — | 0.150 |
| Arrhythmia | 0% | 0% | 0% | 0% | — | — |
| ALT increased | 2 (6.7%) | 5 (16.7%) | 0% | 2 (6.7%) | 0.150 | 0.228 |
| AST increased | 2 (6.7%) | 5 (16.7%) | 0% | 2 (6.7%) | 0.150 | 0.228 |